<DOC>
	<DOC>NCT00116207</DOC>
	<brief_summary>The focus of this project is cardiovascular diabetic autonomic neuropathy (DAN). DAN affects the nerves that control heart rate and blood flow to the heart in people with diabetes. DAN may cause problems with the rhythm of the heartbeat or decrease blood flow to the heart. Three medications will be tested for their effectiveness in DAN.</brief_summary>
	<brief_title>An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Type 1 diabetes A1C &lt;9% Mild neuropathy Mild retinopathy Mild nephropathy History of drug or alcohol dependence, heart disease, viral illness, liver disease, advanced kidney disease Pregnant or nursing Severely overweight</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Oxidative Stress</keyword>
	<keyword>Diabetic Complications</keyword>
	<keyword>Neuropathy</keyword>
</DOC>